SPY468.76+9.97 2.17%
DIA358.42+5.60 1.59%
IXIC15,680.28+455.13 2.99%

Nabriva Announces Availability Of XENLETA In A 10-count Oral Pack

Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formulation

Benzinga · 11/11/2021 07:04

Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formulation of XENLETA® (lefamulin) is now available in a 10-count oral pack in the U.S. through major specialty distributors.
 

XENLETA is the first oral and IV treatment in the pleuromutilin class of antibiotics. XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP). XENLETA has a novel mechanism of action that targets a binding site on bacterial cells that is different from existing antibiotics, resulting in a low propensity for the development of resistance, as well as a lack of cross-resistance with antibiotic classes commonly used for the treatment of CABP.

"This new package size offers pharmacies an option to expand product availability in a cost-effective way to service their local patients and physicians by providing patients a convenient package that contains a complete 5-day course of oral treatment for CABP," said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. "Our community-based sales force is excited to communicate the availability of the 10-count oral pack – or ‘X' pack to their target customers."